Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:AKCA's Cash-to-Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NAS:AKCA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AKCA' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
NAS:AKCA's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NAS:AKCA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:AKCA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -443.59
NAS:AKCA's ROE % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NAS:AKCA: -443.59 )
Ranked among companies with meaningful ROE % only.
NAS:AKCA' s ROE % Range Over the Past 10 Years
Min: -443.59  Med: -332.93 Max: -222.27
Current: -443.59
-443.59
-222.27
ROA % -216.85
NAS:AKCA's ROA % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NAS:AKCA: -216.85 )
Ranked among companies with meaningful ROA % only.
NAS:AKCA' s ROA % Range Over the Past 10 Years
Min: -216.85  Med: -201.4 Max: -185.94
Current: -216.85
-216.85
-185.94
ROC (Joel Greenblatt) % -89002.14
NAS:AKCA's ROC (Joel Greenblatt) % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NAS:AKCA: -89002.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AKCA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1228440  Med: -658721.07 Max: -89002.14
Current: -89002.14
-1228440
-89002.14
GuruFocus has detected 1 Warning Sign with Akcea Therapeutics Inc $NAS:AKCA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKCA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:AKCA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: »  
Compare:NYSE:GPMT, NAS:ATNX, NAS:CGBD, NAS:ADOM, NYSE:BY, NAS:DOVA, NAS:GTHX, NYSE:APRN, NYSE:SAFE, NAS:SGH, NYSE:WOW, NAS:MRSN, NYSE:SMHI, NAS:NESR, NAS:MMDM, NYSE:ETX, NAS:TNTR, NAS:ALRN, NAS:PIXY, NAS:APPN » details
Headquarter Location:USA
Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.

Ratios

vs
industry
vs
history
EV-to-EBIT -12.22
AKCA's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKCA: -12.22 )
Ranked among companies with meaningful EV-to-EBIT only.
AKCA' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.86  Med: 0 Max: 0
Current: -12.22
-11.86
0
EV-to-EBITDA -12.24
AKCA's EV-to-EBITDA is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKCA: -12.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKCA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.87  Med: 0 Max: 0
Current: -12.24
-11.87
0
Current Ratio 0.32
AKCA's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKCA: 0.32 )
Ranked among companies with meaningful Current Ratio only.
AKCA' s Current Ratio Range Over the Past 10 Years
Min: 0.32  Med: 3.16 Max: 5.99
Current: 0.32
0.32
5.99
Quick Ratio 0.32
AKCA's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKCA: 0.32 )
Ranked among companies with meaningful Quick Ratio only.
AKCA' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 3.16 Max: 5.99
Current: 0.32
0.32
5.99

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -8.19
AKCA's Earnings Yield (Greenblatt) % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKCA: -8.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKCA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.42  Med: 0 Max: 0
Current: -8.19
-11.42
0

More Statistics

EPS (TTM) $ -2.88
Short Percentage of Float0.00%
52-Week Range $8.10 - 14.00
Shares Outstanding (Mil)64.20

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}